INDIANAPOLIS--(BUSINESS WIRE)--Wolters Kluwer Health, a leading global provider of information for healthcare professionals and students, today announced that its Medi-Span Controlled Substances Drug File has been selected by Health Market Science (HMS), a leading supplier of provider data and end-to-end solutions that address data management, regulatory compliance and market intelligence, for integration with HMS’s Prescriber Eligibility® (PE) solution. The enhanced solution will provide the industry with near real-time validation of prescriptive authority for scheduled drugs at the U.S. state and territory level to reduce the risk of regulatory fines and improve third party reimbursement rates, including Medicaid.
Medi-Span has been a leading provider of comprehensive drug information and drug interaction database solutions for more than 35 years. The Controlled Substances File can be implemented to assist pharmacists in dispensing settings to meet mandatory compliance with U.S. regulations of controlled substances by providing regulation schedules, Prescription Drug Monitoring Program (PDMP), and Automation of Reports and Consolidated Orders System (ARCOS) in one data resource.
David Del Toro, Vice President & General Manager, Clinical Drug Information, Wolters Kluwer Health, Clinical Solutions comments, “We are excited about the relationship with HMS, as the data contained within our Controlled Substance File truly gains a unique level of granularity when coupled with the Prescriber Network data provided to the HMS clientele.”
Health Market Science's PE solution ensures real-time, point-of-service compliance checks against all submitted pharmacy claims before they are transmitted to payers. PE leverages data from the HMS Provider MasterFile™ a database of 8 million healthcare practitioners, nearly half a million healthcare organizations as well as the affiliations between them. “By integrating Medi-Span’s controlled substances module, Prescriber Eligibility customers will have ready access to state-level drug schedules for prescriber verification,” said Craig Ford, senior vice president, Pharmacy and Government Sales. “With the escalating scrutiny on controlled substance prescribing, this solution enhancement will ensure controlled substance prescriptions are properly verified according to state regulations.”
Integration of the Medi-Span data with HMS’s PE solution is planned in the early half of 2014.
About Wolters Kluwer Health
Wolters Kluwer Health is a leading global provider of information, business intelligence and point-of-care solutions for the healthcare industry. Serving more than 150 countries and territories worldwide, Wolters Kluwer Health’s customers include professionals, institutions and students in medicine, nursing, allied health and pharmacy. Major brands include Health Language®, Lexicomp®, Lippincott Williams & Wilkins, Medicom®, Medknow, Ovid®, Pharmacy OneSource®, ProVation® Medical and UpToDate®.
Wolters Kluwer Health is part of Wolters Kluwer, a market-leading global information services company. Wolters Kluwer had 2012 annual revenues of €3.6 billion ($4.6 billion), employs approximately 19,000 people worldwide, and maintains operations in over 40 countries across Europe, North America, Asia Pacific, and Latin America. Follow our official Twitter handle: @WKHealth.
